Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher.

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment follows recent meetings that left analysts with a positive outlook on the company's future financial performance.

Barclays raised the firm’s price target on Boston Scientific (BSX) to $118 from $111 and keeps an Overweight rating on the shares. The firm